+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ORCHPHARMA

Orchid Pharma Share Price

₹1,045.65 +11.75 (1.14%)
New 52W High in past week

14 Aug, 2026 3:54 PM (IST)

Orchid Pharma live price: ₹1,045.65. It opened at ₹1,042 vs previous close ₹1,034; intraday high/low: ₹1,070/₹1,035. The 50 & 200 DMA stand at ₹962.40/₹825.50.

Orchid Pharma Performance

  • Today's Low
  • ₹1,035
  • Today's High
  • ₹1,070
  • 52 Week Low
  • ₹480
  • 52 Week High
  • ₹1,133
  • Open Price₹1,042
  • Previous Close₹1,034
  • Volume70,343
  • 50 DMA₹962.40
  • 100 DMA₹877.60
  • 200 DMA₹825.50

Orchid Pharma Chart

Investment Returns

  • Over 1 Month -0.69%
  • Over 3 Month + 45.38%
  • Over 6 Month + 57.37%
  • Over 1 Year + 39.75%

Smart Investing Starts Here Start SIP with Orchid Pharma for Steady Growth!

Invest Now

Orchid Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 722.5
  • PEG Ratio
  • -8
  • Market Cap Cr
  • 6,262
  • P/B Ratio
  • 4.8
  • Average True Range
  • 46.4
  • EPS
  • 1.4
  • Dividend Yield
  • 0
  • MACD Signal
  • 19.9
  • RSI
  • 56.95
  • MFI
  • 60.68

Latest Stock News Updates

Orchid Pharma Ltd - 524372 - Statement Of Deviation Or Variation For The Quarter Ended June 30, 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional Placement

Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.

Orchid Pharma Ltd - 524372 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.

Orchid Pharma Ltd - 524372 - Outcome Of Board Meeting Held For Considering And Approving Revised Audited Financial Results For The Year Ended March 31, 2026 Pursuant To Scheme Of Merger.

Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger

Orchid Pharma Financials

Orchid Pharma Technicals

EMA & SMA

Current Price
₹1,045.65
+ 11.75 (1.14%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹1,020.70
  • 50 Day
  • ₹962.40
  • 100 Day
  • ₹877.60
  • 200 Day
  • ₹825.50

Resistance and Support

1050.22 Pivot Speed
  • R3 1,100.40
  • R2 1,085.20
  • R1 1,065.40
  • S1 1,030.40
  • S2 1,015.20
  • S3 995.40

Orchid Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-14 Quarterly Results
2026-08-01 Allotment of Equity Shares
2026-05-25 Audited Results
2026-02-11 Quarterly Results
2025-11-11 Quarterly Results

Orchid Pharma Shareholding Pattern

69.84%
19.93%
8.62%
0.82%
0.8%

About Orchid Pharma

Orchid Pharma 01 the leading ptlarrna<;eutlcal oompanies in India haad quartered In Channai and Involved in the davelopment, manufacture and marketing of diverse bulk aeWes. formulationS and nutraceu~cals with exports spanning over 40 counllies. Orcttid's world class manufacturing infrasl1uclure Include USFDA compliant API and Finished Dosage Form faciliUes at Chennai In India. OrctIid lias dediCilted stale-of-art and GLP compliant R&D infrastructure fOf Procen researetl, Drug Discovery and Pllarmaceut!cal researen at Chennal, India. View More
  • NSE Symbol
  • ORCHPHARMA
  • BSE Symbol
  • 524372
  • ISIN
  • INE191A01027

Similar Stocks to Orchid Pharma

Orchid Pharma FAQs

Orchid Pharma share price is ₹1,045 As on 15 August, 2026 | 10:42

The Market Cap of Orchid Pharma is ₹6261.9 Cr As on 15 August, 2026 | 10:42

The P/E ratio of Orchid Pharma is 722.5 As on 15 August, 2026 | 10:42

The PB ratio of Orchid Pharma is 4.8 As on 15 August, 2026 | 10:42

The 52 week High & Low of Orchid Pharma is ₹1133/₹480 respectively As on 15 August, 2026 | 10:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23